ProShares Ultra NASDAQ Biotechnology
BIB
41 hedge funds and large institutions have $34.8M invested in ProShares Ultra NASDAQ Biotechnology in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 8 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
49% more capital invested
Capital invested by funds: $23.3M → $34.8M (+$11.5M)
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
8% more funds holding
Funds holding: 38 → 41 (+3)
1.97% more ownership
Funds ownership: 6.74% → 8.7% (+2%)
5% less call options, than puts
Call options by funds: $13.2M | Put options by funds: $13.9M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Howard Capital Management
Roswell,
Georgia
|
+$6.54M |
| 2 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$3.76M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.24M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.07M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$321K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
-$5.37M |
| 2 |
Jane Street
New York
|
-$1.16M |
| 3 |
VF
Virtu Financial
New York
|
-$1.16M |
| 4 |
SAM
Stansberry Asset Management
Westlake,
Texas
|
-$347K |
| 5 |
HF
HRT Financial
New York
|
-$258K |
BIB Hedge Fund Activity: Q3 2018 in Review
41 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2018, worth a combined $34.8M — up 49% from $23.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BIB positions and 8 closed out — a net gain of 3 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Howard Capital Management, opening a new position worth an estimated $6.54M. The largest seller was Opus Point Partners Management, exiting entirely with an estimated $5.37M sold.
- 41 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2018, up from 38 in Q2 2018.
- Funds reported $34.8M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2018, up 49% quarter-over-quarter.
- 11 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2018 and 8 closed out, a net change of +3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2018 was Howard Capital Management, an estimated $6.54M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2018 was Opus Point Partners Management, an estimated $5.37M sold.
Based on aggregated 13F filings for Q3 2018.